Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Nizar Chahin et al.|The Lancet Neurology|2023Cited by 255
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T. Guptill, Henry J. Kaminski, Michael Benatar et al.|Neurology|2023Cited by 26